Enhancing Outcomes in Seborrheic Keratosis: Using a Novel Treatment Solution

July 2019 | Volume 18 | Issue 7 | Supplement Individual Articles | 178 | Copyright © July 2019


Todd E. Schlesinger MD FAAD, Clint Favre

Dermatology and Laser Center of Charleston; Clinical Research Center of the Carolinas, Charleston, SC


cedure. It is important to note that in this application process, only one treatment session was administered per patient. The package insert for Eskata suggests that another treatment may be administered after approximately 3 weeks, if the first treatment did not completely clear the lesions. 

In these cases, HP40 produced sufficient and satisfactory results for destruction of SKs while yielding minimal adverse effects. However, HP40 contains a high concentration of hydrogen peroxide, potentially leading to oxidative damage to areas of the skin with increased irritation, pain, and erythema, if treated improperly. To maximize successful clearance of SK and minimize adverse effects, physicians and other practitioners can consider the following techniques. 

The first key to treatment success comes with thorough saturation of the lesion during each application. The provider applying the topical solution must treat the lesion with the recommended number application (four) sessions to achieve the optimal clinical endpoint, which is a thorough whitening of the lesion and surrounding skin (approximately 1 millimeter). The affected area should display no evidence of bleeding, erosion, or blister formation. If one of these adverse effects occurs, the lesion has been saturated with too much topical solution, and the provider should move on to a different lesion. The lesion surface should be uniformly wet without any excessive running or dripping onto the surrounding area of the skin. If any residual solution drips onto the surrounding unaffected skin, the provider should remove the excess solution with a clean absorptive wipe. It is important to use a paper towel or tissue because residual solution may still reside on the unaffected skin, which may increase the risk of adverse effects. For best results, allow the lesion to completely dry before another application. The provider should wait the recommended 1 minute between applications and ensure that the topical solution is applied only to targeted lesions. 


After treatment with HP40, it is important to leave each lesion dry without applying a dressing or ointment for 4 hours so the hydrogen peroxide solution will have maximum effect. After 4 hours, the patient should apply an occlusive dressing to the treated areas. The targeted areas should remain covered with a bandage and lubricated as needed until the SKs slough off naturally. HP40 is a novel FDA approved treatment for seborrheic keratosis. With careful patient selection and attention to best-practice treatment technique, patients can benefit from removal of unsightly lesions with minimized adverse effects. 

REFERENCES

  1. Coyne JD. Classification of the seborrheic keratosis. Int J Surg Pathol. 2016;24(1):51-52.
  2. Weedon D. Skin pathology, 2nd ed. Chapter 31: Tumors of the epidermis. Churchill Livingstone. 2002:765-771.
  3. Geethu Francis Alapatt DS, Ramesh Bhat M. A clinicopathological and dermoscopic correlation of seborrheic keratosis. Indian J Dermatol. 2016;61(6):622-627.
  4. Yeatman JM, Kilkenny M, & Marks R. The prevalence of seborrheic keratoses in an Australian population: does exposure to sunlight play a part in their frequency? Br J Dermatol. 1997;137(3):411-4.
  5. Heidenreich B, Denisova E, Rachakonda S, et al. Genetic alterations in seborrheic keratosis. Oncotarget. 2017
  6. Del Rosso JQ. A closer look at seborrheic keratoses: patient perspectives, clinical relevance, medical necessity, and implication for management. J Clin Aesthet Dermatol. 2017;10(3):16-25
  7. Minagawa A. Dermoscopy-pathology relationship in seborrheic keratosis. J Dermatol. 2017;44(5):518-524.
  8. H. Kittler et al. Standardization of terminology in dermoscopy/dermatoscopy: Results of the third consensus conference of the International Society of Dermoscopy. J Am Acad Dermatol. 2016;74:1093-106.
  9. Takenouchi T. Key points in dermoscopic diagnosis of basal cell carcinoma and seborrheic keratosis in Japenese. J Dermatol. 2011;38:59-65
  10. Ferrara G, Argenziano G, Soyer HP, Staibano S, Ruocco E, DeRosa G. Dermoscopic-pathologic correlation: an atlas of 15 cases. Clin Dermatol. 2002;20:228-235
  11. Jackson JM, Alexis A, Berman B, Berson DS, Taylor S, Weiss JS. Current understanding of seborrheic keratosis: prevalence, etiology, clinical presentation, diagnosis, and management. J Drugs Dermatol. 2015;14(10):1119-25.
  12. Ranasinghe GC, Friedman AJ. Managing seborrheic keratoses. evolving strategies for optimizing patient outcomes. J Drug Dermatol. 2017;16(11)1064-1068.
  13. Andrews MD. Cryosurgery for common skin conditions. AM Fam Physician. 2004;69(10):2356-72.
  14. Farhangian ME, Snyder A, Huang KE, Doerfler L, Huang WW, Feldman SR. Cutatenous crysorugery in the United States. J Dermatolog Treat. 2016;27(1):91-94.
  15. Graham G, Barham K. Cryosurgery. Curr Probl Dermatol. 2003;15(6):229-250.
  16. Wood LD, Stucki JK, Hollenbeak CS, Miller JJ. Effectiveness of cryosurgery vs curettage in the treatment of seborrheic keratoses. JAMA Dermatol. 2013;149(1):108-109.
  17. Kao S, Kiss A, Efimova T, Friedman AJ. Managing seborrheic keratosis: evolving strategies and optimal therapeutic outcome. J Drugs Dermatol. 2018;17(9):933-940.
  18. Herron MD, Bowen AR, Krueger GG. Seborrheic keratoses: a study comparing the standard cryosurgery with topical calcipotriene, topical tazarotene, and topical Imiquimod. Int J Dermatol. 2004;43(4):300-2
  19. DuBois JC, Jarratt M, Beger BB, Bradshaw M, Powala CV, Shanler SD. A-101 a proprietary topical formulation of high-concentration hydrogren peroxide solution: A randomized, double-blind, vehicle-controlled, parallel group study of the dose-response profile in subjects with seborrheic keratosis of the face. Dermatol Surg. 2018;44(3):330-340.
  20. Yang B, Yang Q, Yang X, et al. Hyperoside protects human primary melanocytes against H2O2-induced oxidative damage. Mol Med Rep. 2016;13(6):4613-4619.
  21. Kao S, Kiss A, Efimova T, Friedman A. An ex-vivo evaluation of cytotoxicity and melanocyte viability after A-101 hydrogen peroxide topical solution 40% or cryosurgery treatment in sebhorreic keratosis lesions. J Am Acad Dermatol. 2018;79(4):767-768.
  22. Bauman LS, Blauvelt A, Draelos ZD, et al. Safety and efficacy of hydrogen peroxide topical solution, 40% (w/w), in patients with seborrheic keratoses: results from 2 identical, randomized, double-blind, placebo-controlled, phase 3 studies (A-101-SEBK-301/302). J Am Acad Dermatol. 2018;79(5):869-877.
Close Menu